格雷夫斯病患者采用抗甲状腺药物与放射性碘或手术治疗的长期效果比较：文献综述。
Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves' disease: A review of the literature.
机构信息
Division of Endocrinology, Diabetes and Nutrition, Mayo Clinic, Rochester, MN, USA.
Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
出版信息
Clin Endocrinol (Oxf). 2021 Jul;95(1):3-12. doi: 10.1111/cen.14374. Epub 2020 Dec 6.
BACKGROUND
The management of Graves' disease (GD) in the US is shifting towards increased use of anti-thyroid drugs (ATD). If patients fail to achieve remission after a standard course of therapy of 12-18 months, long-term treatment with ATD (≥24 months) may be chosen over definitive therapy with radioiodine (RAI) or surgery. Clinicians will need to contrast this strategy to ablative therapies as they help patients in decision making.
SUMMARY
Review of the literature illustrates that long-term ATD delivers euthyroidism with minimal complications, low financial cost and with an advantageous profile regarding quality of life (QoL) and other biological outcomes.
CONCLUSIONS
Long-term ATD is a viable alternative to ablative therapies in the management of GD offering advantages across multiple patient centred outcomes. Decision making must factor differences in this approach compared to ablative therapies and ultimately be tailored to individualized patient situations.
背景
美国 Graves 病（GD）的治疗管理正朝着增加使用抗甲状腺药物（ATD）的方向转变。如果患者在标准疗程 12-18 个月后未达到缓解，那么可能会选择长期使用 ATD（≥24 个月），而不是放射性碘（RAI）或手术等确定性治疗。在帮助患者做出决策时，临床医生需要将这种策略与消融性疗法进行对比。
摘要
文献回顾表明，长期 ATD 可实现甲状腺功能正常，并发症最小，财务成本低，并且在生活质量（QoL）和其他生物学结果方面具有优势。
结论
长期 ATD 是 GD 管理中消融性疗法的可行替代方案，在多个以患者为中心的结局方面具有优势。决策必须考虑到与消融性疗法相比，这种方法的差异，并最终根据患者的具体情况进行调整。
Zotero 插件